APTO-253

Roth Capital has upgraded Aptose Biosciences Inc (NASDAQ: APTO) to Buy from Neutral "on an expected inflection point in the near-term, namely the allowance for APTO-253 to return to the clinical." Belonging to a new small molecules class, APTO-253 "is designed to induce a silent tumor-suppressive...